Skip to content

Parish & Company LLC

  • Home
  • About
  • Services
  • Investment Philosophy
  • Selected Media Archive
  • Blog
    • Latest Posts
    • Blog Archive
  • Contact

Category: Drug companies

bill parish, Drug companies, Oregon-PERS, Politics

MSCI Health Care Index: A Good Measure or a Pyramid Scheme Enabler? Case Study: Johnson and Johnson and Pfizer

Index based investment using a company's total stock market value is a great concept and indexes such as the S&P 500 generally provide solid low cost diversification. Unfortunately, Wall Street has now applied this concept to "sectors" of the stock market without adjusting for the size of individual companies.  This is not only exposing investors … Continue reading MSCI Health Care Index: A Good Measure or a Pyramid Scheme Enabler? Case Study: Johnson and Johnson and Pfizer

August 24, 2017June 9, 20202017, BlackRock, CEO, Collateral, Compensation expense, Derivatives, Diversification, Drug costs, Drug makers, Drugs, Economy, ETF, Fidelity, Foundations, Health insurance, Healthcare, Healthcare Index, Henry Fernandez, Indexes, Johnson and Johnson, Merck, Morgan Stanley, Mortgage, MSCI, MSCI CEO, MSCI Health Care Index, Pfizer, Regeneron, restricted stock, Royalty Pharma, S&P 500, SPDR, State Street, Stock Market, Stock options, UnitedHealth Group, Vanguard, Vanguard funds, VHT, Wall Street, XLV

Search

 

Loading Comments...